Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade® to Remsima®? An Observational Study

Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade® to Remsima®? An Observational Study

Background: Since the late ‘90s, infliximab (Remicade®) is being used successfully to treat patients with several non-infectious immune mediated inflammatory diseases (IMIDs). In recent years, infliximab biosimilars, including Remsima® were introduced in clinical practice.Aim: To investigate the int...

Full description

Bibliographic Details
Main Authors: Laixi Xue, K. van Bilsen, M. W. J. Schreurs, M. E. J. van Velthoven, T. O. Missotten, A. A. H. J. Thiadens, R. W. A. M. Kuijpers, P. van Biezen, V. A. S. H. Dalm, J. A. M. van Laar, M. A. W. Hermans, W. A. Dik, P. L. A. van Daele, P. M. van Hagen
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Medicine
Subjects:
infliximab
Remicade®
Remsima®
CTP 13
biosimilar
rare or orphan immune-mediated inflammatory diseases (IMIDs)
Online Access:https://www.frontiersin.org/article/10.3389/fmed.2020.00418/full

Internet

https://www.frontiersin.org/article/10.3389/fmed.2020.00418/full

Similar Items